HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- (4- methoxybenzylidene)thiazolidine- 2,4- dione

used to treat concanavalin A-induced liver injury; structure in first source

Also Known As:

SKLB 010; SKLB-010; SKLB010

Networked: 5 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - Thiazolidinediones: 2250
      - 5-(4-methoxybenzylidene)thiazolidine-2,4-dione: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Thiazolidinediones: 2250
        5-(4-methoxybenzylidene)thiazolidine-2,4-dione: 5

Experts

1.	Ma, Liang: 5 articles (08/2014 - 11/2010)
2.	Chen, Lijuan: 4 articles (08/2014 - 11/2010)
3.	Zheng, Hao: 4 articles (02/2012 - 11/2010)
4.	Ye, Xia: 2 articles (02/2012 - 09/2011)
5.	Wang, Xianhuo: 2 articles (09/2011 - 11/2010)
6.	Luo, Youfu: 2 articles (01/2011 - 11/2010)
7.	Ma, Yinghua: 2 articles (01/2011 - 11/2010)
8.	Qi, Baowen: 2 articles (01/2011 - 11/2010)
9.	Wei, Xin: 2 articles (01/2011 - 11/2010)
10.	Wei, Yuquan: 2 articles (01/2011 - 11/2010)

Related Diseases

1.	Hepatitis 09/10/2011 - "SKLB010 is currently under development as a potential therapeutic agent for the treatment of acute hepatitis and rheumatoid arthritis. " 11/01/2010 - "In our previous study, we have demonstrated that (Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione (SKLB010), a novel analogue of thiazolidinediones, showed protection against concanavalin A (Con A)-induced hepatitis via inhibiting the migration of macrophages and the expression of pro-inflammatory mediators. "
2.	Acute Liver Failure (Fulminant Hepatic Failure) 08/01/2014 - "Protective effect of SKLB010 against D-galactosamine/lipopolysaccharide-induced acute liver failure via nuclear factor-κB signaling pathway in macrophages." 08/01/2014 - "SKLB010, a derivative of thiazolidinediones, has been proved to be effective in protecting mice from acute liver failure caused by concanavalin A and carbon tetrachloride in our previous work. "
3.	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/01/2011 - "In conclusion, our results showed that SKLB010 could attenuate the BLM-induced pulmonary fibrosis in vivo and therefore be a promising anti-fibrogenic candidate." 01/01/2011 - "The present study aimed to investigate the preventive effect of SKLB010 in bleomycin-induced pulmonary fibrosis and further explore the underlying mechanisms. "
4.	Body Weight (Weight, Body) 11/01/2010 - "Our results also indicated that oral administration of 50 mg/kg SKLB010 markedly resulted in a clear suppression of clinical signs compared to untreated groups, showing as markedly reduction of paw swelling and inhibition of body weight decreasing. " 02/21/2012 - "Rats were injected intraperitoneally with a mixture of CCl₄ (1 mL/kg body weight) and olive oil [1:1 (v/v)] twice a week for 4 wk. In the SKLB010-treated groups, SKLB010 (100 mg/kg) was given once daily by oral gavage for 4 wk after CCl₄ administration. "
5.	Neoplasms (Cancer) 01/01/2011 - "Meanwhile, SKLB010 inhibited the overexpression of tumor growth factor (TGF)-β1 and Smad3 in a dose-dependent manner. "

Related Drugs and Biologics

1.	Thiazolidinediones
2.	Concanavalin A
3.	Carbon Tetrachloride (Tetrachloromethane)
4.	indium-bleomycin
5.	Intercellular Signaling Peptides and Proteins (Growth Factors)
6.	Lipopolysaccharides
7.	Galactosamine
8.	Collagen
9.	Olive Oil

Related Therapies and Procedures

1.	Oral Administration